High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy

Liver International

Volumn 35, Issue 2, 2015, Pages 510-517

  Verna, Elizabeth C ^a   Shetty, Kirti ^b   Lukose, Thresiamma ^a   Terry, Nicole ^b   Mentore, Kimiknu ^b   Olsen, Sonja K ^a   Fox, Alyson N ^a   Dove, Lorna M ^a   Brown, Robert S ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Hepatitis C; Liver transplant; Protease inhibitor; Treatment

Indexed keywords

ALBUMIN; BILIRUBIN; BOCEPREVIR; CREATININE; ERYTHROPOIETIN; FILGRASTIM; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PROLINE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; CHILD TURCOTTE PUGH SCORE; CHOLECYSTITIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; OBSERVATIONAL STUDY; OPTIC NEURITIS; OROPHARYNX CANDIDIASIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VISUAL IMPAIRMENT; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PROSPECTIVE STUDY;

DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 84921565788     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12616     Document Type: Article

References (23)

1. Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1003-19.
2. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-62.
3. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.
4. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: e1612.
5. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006; 44: 1675-84.
6. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.
7. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.
8. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-28.
9. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-15.
10. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
11. Hezode C, Forestier N, Dusheiko G, et al., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
12. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
13. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
14. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
15. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
16. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
17. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
18. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.
19. Fontaine H, Hezode C, Dorival C, et al. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIV). J Hepatol 2013; 58: S25-44.
20. Curry MP, Forns X, Chung RT, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV Infection after liver transplantation. Hepatology 2013; 58: 314S-5S.
21. Burton JR, O'Leary JG, Verna EC, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014; In Press.
22. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
23. Samuel D, Charlton M, Gane E, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective. Multicenter study. J Hepatol 2014; 60: S499.